Last week, there was a tremendous display of confidence in Opko Health Inc. (NYSE:OPK) when CEO Phillip Frost made several discretionary purchases on …
Opko Health Inc.(NYSE:OPK) announced that the company will present new data on its long-acting clotting Factor VIIa-CTP (MOD-5014) at the International Society on Thrombosis …
Opko Health Inc. (NYSE:OPK) and Bio-Reference Laboratories, Inc.
Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a price target of $12, which represents a potential upside …
In a research report issued today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on Opko Health (NYSE:OPK) with a $12 price target, following yesterday’s news …
